OmniAb/$OABI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About OmniAb
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
- Ticker
- $OABI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 89
- Headquarters
- EmeryVille, United States
- Website
- www.omniab.com
OmniAb Metrics
BasicAdvanced
$743M
-
-$0.34
-
-
Price and volume
Market cap
$743M
52-week high
$5.43
52-week low
$1.30
Average daily volume
1.4M
Financial strength
Current ratio
4.212
Quick ratio
3.963
Long term debt to equity
0.057
Total debt to equity
0.073
Profitability
EBITDA (TTM)
-35.272
Gross margin (TTM)
97.65%
Net profit margin (TTM)
-108.11%
Operating margin (TTM)
-106.87%
Effective tax rate (TTM)
0.92%
Revenue per employee (TTM)
$450,000
Management effectiveness
Return on assets (TTM)
-8.94%
Return on equity (TTM)
-16.51%
Valuation
Price to revenue (TTM)
16.339
Price to book
2.99
Price to tangible book (TTM)
14.29
Growth
Revenue change (TTM)
90.63%
Earnings per share change (TTM)
-41.61%
3-year revenue growth (CAGR)
-14.66%
3-year earnings per share growth (CAGR)
4.33%
What the Analysts think about OmniAb
Analyst ratings (Buy, Hold, Sell) for OmniAb stock.
Analyst projections of the future price of OmniAb stock.
Bulls say / Bears say
OmniAb has a broad partner pipeline: 110 partners supported 425 programmes at June 2026, including 34 clinical or approved assets, and the company sees up to 19 trial readouts through 2027. Positive results could trigger further milestones and royalties. (Quartr)
OmniAb has opened its xPloration platform to all customers, targeting a market it estimates at more than US$500 million. It expects xPloration revenue of US$2–3 million in 2026 to double in each of the following two years, offering a possible second growth stream. (MarketScreener)
Milestone income is hard to predict: management said it can vary significantly by quarter and that 2026 receipts were more front-loaded than in 2025. That leaves near-term revenue exposed to changes in partners’ timetables. (The Motley Fool)
OmniAb remains loss-making: second-quarter operating costs were US$20.1 million against revenue of US$13.4 million, with a net loss of US$5.9 million. Its 2026 forecast still puts costs and operating expenses at US$84–88 million, well above expected revenue of US$32–36 million. (OmniAb)
OmniAb has little or no control over partners’ development plans, regulatory strategies or commercialisation, and warns that drug development is inherently uncertain. Delays, cancellations or failed approvals could therefore prevent expected milestones and royalties from materialising. (OmniAb)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
OmniAb Financial Performance
Revenues and expenses
OmniAb Earnings Performance
Company profitability
Upcoming events
No upcoming events
OmniAb News
AllArticlesVideos
Funds containing OmniAb
Fund name | Fund size | $OABI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.05% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.05% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.